

MyoD expression marks the onset of skeletal myogenesis in *Myf-5* mutant mice

Thomas Braun^{1,*}, Eva Bober¹, Michael A. Rudnicki², Rudolf Jaenisch³ and Hans-Henning Arnold¹

¹Department of Cell and Molecular Biology, University of Braunschweig, Spielmannstrasse 7, 38106 Braunschweig, FRG

²Institute for Molecular Biology and Biotechnology, McMaster University, Hamilton, Canada

³Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, USA

*Author for correspondence

SUMMARY

The expression pattern of myogenic regulatory factors and myotome-specific contractile proteins was studied during embryonic development of *Myf-5* mutant mice by in situ hybridization and immunohistochemistry.

In contrast to somites in wild-type embryos, no expression of myogenin and Myf-6 (MRF4), or any other myotomal markers was detected in mutant animals at E9.0 and E10.0 indicating that *Myf-5* plays a crucial role during this developmental period. Significantly, the onset of *MyoD* expression in rostral somites of E10.5 embryos was unaffected by the *Myf-5* mutation suggesting that the activation of the *MyoD* gene occurs independently of *Myf-5* at the correct developmental time. Immediately after the activation of *MyoD* myogenin transcripts and protein accumu-

lated within the myotome. The first contractile proteins of the sarcomeric apparatus appeared slightly later. By E11.5 the expression of muscle markers were indistinguishable between wild-type and *Myf-5* mutant mice.

The migration of muscle precursor cells that leave the somites to form limb musculature was monitored in *Myf-5*-mutant mice by Pax-3 expression. Pax-3-positive cells were equally found in somites and limbs of E10.0 wild-type and mutant mice indicating that myogenic factor expression at the level of somites is not a prerequisite for determination and subsequent migration of limb precursor cells.

Key words: *MyoD*, expression, skeletal myogenesis, *Myf-5*, mouse

INTRODUCTION

The development of skeletal muscle during embryogenesis is a multistep process, which involves commitment of mesodermal progenitor cells to the myogenic lineage, enlargement of this cell compartment and differentiation events resulting in highly specialized postmitotic cells. Subsequently, these cells undergo maturation and diversification to form functional muscle tissue in response to various environmental and cell autonomous influences (reviewed by Cossu and Molinaro, 1987).

The initial steps of myogenic differentiation take place in the somites which form in a rostrocaudal direction by segmentation of the paraxial mesoderm. As somites mature, they become compartmentalized into dermomyotome and sclerotome which give rise to skeletal muscle and axial skeleton, respectively (Christ et al., 1978; reviewed by Keynes and Stern, 1988).

A family of genes including *MyoD*, *myogenin*, *Myf-5* and *Myf-6* (*MRF4*) has been identified, which controls at least some of these developmental steps (reviewed by Weintraub et al., 1991; Arnold and Braun, 1993). Their role as key regulators of myogenic determination and differentiation events was

proposed by tissue culture experiments in which all four factors can convert a variety of different cell types into muscle cells when expressed from constitutive promoters (reviewed by Olson and Klein, 1994).

Other important clues came from the developmental pattern of myogenic factor expression. In situ hybridization studies suggested a sequential activation of the factors in somites with *Myf-5* being expressed first, followed by myogenin, *Myf-6* and *MyoD*. Importantly, *Myf-5* transcription precedes the appearance of contractile proteins suggesting that it may have a crucial role in the initiation of muscle development (reviewed by Buckingham, 1992; Arnold and Braun, 1993).

Mouse mutants, recently generated by homologous recombination in embryonic stem cells, have provided new tools to establish the role of myogenic factors in vivo and distinguish between individual functions of different family members. Inactivation of the *MyoD* gene has no severe effects upon skeletal muscle differentiation; however, we noted that *Myf-5* expression remains high presumably compensating for the loss of *MyoD* (Rudnicki et al., 1992). Similarly, mice homozygous for a *Myf-5* mutation do not display a striking muscle phenotype at birth, but die perinatally due to a severe malformation of the ribs (Braun et al., 1992). Inactivation of both the

MyoD and *Myf-5* genes, however, results in mice completely devoid of skeletal muscle lacking both myofibers and myoblasts (Rudnicki et al., 1993). In contrast to these results, targeted mutation of the *myogenin* gene leads to decreased myoblast differentiation resulting in muscles with only few myofibers but apparently normal numbers of mononucleated myoblasts (Hasty et al., 1993; Nabeshima et al., 1993). The mutant myoblasts express *MyoD* and are capable of differentiating into myotubes in culture (Nabeshima et al., 1993). These observations imply that *Myf-5* and/or *MyoD* control the determination of myoblasts and that *myogenin* is involved in the terminal differentiation process.

We have shown previously that the skeletal musculature in *Myf-5* mutant mice appears essentially normal at birth, whereas no muscle-specific terminal differentiation markers were detected in somites of E10.5 mutant embryos (Braun et al., 1992). Based on these observations, we suggested that in the mutant myotome formation may be delayed but that eventually normal muscle cells form. In this paper, we present a detailed analysis of the expression of *MyoD*, *myogenin* and *Myf-6* (*MRF4*), as well as sarcomeric marker genes, in *Myf-5*-mutant embryos in an effort to assess which of these genes may initiate muscle formation in somite development.

Our results show that in the absence of *Myf-5* myogenesis is considerably delayed and begins in cranial somites at E10.5 with the expression of *MyoD*. The activation of *MyoD* at the correct developmental time suggests that it is independent on *Myf-5*. Activation of *MyoD* therefore, constitutes a second distinct entry point into the myogenic program, in addition to and independent of *Myf-5* expression. We furthermore demonstrate that the migration of *Pax-3*-expressing cells from the dermomyotome to the limb buds is unaffected in *Myf-5* mutants, even in the complete absence of myogenic factors. These findings indicate that migratory dermomyotomal cells constituting the prospective muscle cell population of the limbs acquire their fate entirely independent of the myotome and any signals it may provide.

MATERIALS AND METHODS

Mice

The generation of *Myf-5* mutant mice has been described previously (Braun et al., 1992). Most of the analyses were performed with 129Sv/J^{Myf5^{m1}} mice backcrossed two or three times to C57BL6 or BALB/c mice. Crosses of inbred 129Sv/J^{Myf5^{m1}} mice generally yielded fewer embryos, which were slightly delayed in development but with virtually identical phenotype. Embryos were staged by the number of somites and by counting the appearance of the vaginal plug as day 0.5 p.c.

Material for genotyping of the embryos was obtained by dissection of yolk sac tissue from the embryo proper. Genomic DNA isolated from the yolk sac was cut with *Bam*HI and analyzed on Southern blots using a probe that flanked the mutant *Myf-5* locus as described previously (Braun et al., 1992).

In situ hybridization

Sections of embryos were prepared for in situ hybridization and immunocytochemistry by fixation in 4% paraformaldehyde for 12 hours, followed by dehydration in 0.5 M sucrose in PBS overnight. Embryos were frozen in OCT (Miles Scientific) and sectioned on a cryostat.

Prehybridizations and hybridizations were performed with [³⁵S]UTP-labelled cRNA probes as described (Ott et al., 1991; Sassoon et al., 1989). The cRNA probes for *MyoD*, *myogenin*, *Myf-6* and *Pax-3* were described by Sassoon et al. (1989), Bober et al. (1991) and Bober et al. (1994), respectively.

Immunohistochemistry

Immunocytochemistry was performed on cryostat sections using vectastain elite kits (Braun et al., 1989). The following antibodies were used: mAb MF20 raised against sarcomeric MyHC (kindly provided by D. Fishman, New York), mAb MY32 against fast MyHC (obtained from Sigma Inc.), monoclonal antibodies against desmin and titin (kindly provided by K. Weber, Göttingen), mAb F5D which reacts specifically with *myogenin* but not with other bHLH-proteins (kindly supplied by W. Wright, Dallas).

RESULTS

Myogenic factors and markers for terminal muscle differentiation are absent in somites of E9.5 and E10.25 mutant *Myf-5* embryos

Our initial studies suggested that *Myf-5* is required for the development of early somitic myocytes (Braun et al., 1992). To explore in more detail the *Myf-5* mutant phenotype in early to late somite stage embryos in situ hybridizations and immunocytochemical stainings were performed.

Previous work established that in wild-type mice *Myf-5* is expressed in the segmented paraxial mesoderm from E8 to E13 (Ott et al., 1991). *Myogenin* RNA first appears in the myotomes at E8.5 and continues to be expressed throughout fetal development (Sassoon et al., 1989). *Myf-6* is expressed transiently at E10 and E11 and is re-expressed at E16. It constitutes the most abundant myogenic factor in postnatal life (Bober et al., 1991; Hinterberger et al., 1991). *MyoD* RNA is first detected at E10.5 and remains expressed throughout fetal development (Sassoon et al., 1989).

In contrast to wild-type E9.5 embryos (21-25 somites) in which *myogenin* transcripts were present on virtually every section, we were unable to detect *myogenin* mRNA in *Myf-5*-deficient mice of the same stage (Fig. 1A-D). To ascertain appropriate planes of sectioning through the dermomyotomal layer of somites, control hybridizations were performed on adjacent sections using a *Pax-3* probe. *Pax-3* is expressed in the dorsal part of the neural tube (Goulding et al., 1991), in the myotome and in the neighbouring dermatome (Bober et al., 1994). It constitutes an excellent marker for these compartments since all markers that are restricted to the myotome were negative in *Myf-5* mutant embryos at this stage and could therefore not be used to demonstrate the presence of dermomyotomal structures. As shown in Fig. 1I-L, a similar distribution of *Pax-3* transcripts was found in somites of wild-type and mutant mice. This observation provides evidence that the amount of mesodermal cells within the dermomyotome is not greatly reduced in *Myf-5* mutants and that *Pax-3* expression in the dorsal as well as in the ventral part of the dermomyotome is independent of *Myf-5*.

We next investigated the expression of *MyoD* in the same E9.5 wild-type and mutant embryos. As shown in Fig. 1E-H, no *MyoD* transcripts were found in wild-type or mutant embryos arguing against a compensatory or premature *MyoD* expression as a consequence of the *Myf-5* mutation. Weak




Fig. 1. Comparison of myogenin, MyoD and Pax-3 expression in genotyped wild-type (A,B,E,F,I,J) and *Myf-5* mutant (C,D,G,H,K,L) embryos at the 22-somite stage. Adjacent transverse sections of trunk somites were hybridized with myogenin (B,D), MyoD (F,H) and Pax-3 (J,L) probes. Homozygous mutant embryos do not express myogenin mRNA at

this stage, while Pax-3 mRNA is expressed in the dermomyotome at normal levels. No MyoD transcripts were observed in wild-type and mutant embryos. Corresponding bright-field illuminations are shown to the left of each dark-field panel. Magnifications are 320x.

MyoD in situ hybridization signals were first identified at the 35-somite stage (E10.25) in *Myf-5* mutant embryos (Fig. 2A,B). Transcripts for myogenin and Myf-6 were still undetectable in these embryos, although they were readily identified in wild-type embryos of this stage (data not shown). In contrast, somitic expression of Pax-3 appeared normal (Fig. 2G,H) as already shown in 22-somite-stage (E9.5) embryos.

Several additional myogenic markers such as MyHC, titin, nebulin or desmin were also analyzed by in situ hybridization or immunocytochemistry and found to be absent from somites of E10.25 (32 somites) and E10.5 (40 somites) mutant embryos (Fig. 3D,F,G). This confirms that virtually no muscle cell differentiation occurred up to this developmental stage in the absence of *Myf-5*.

Myogenesis in mutant *Myf-5* embryos is initiated by MyoD which is expressed at the correct developmental time

Because *Myf-5* mutant pups had apparently normal muscle tissue at birth, it was possible that expression of other myogenic factors compensated for the lack of *Myf-5* resulting in normal muscle development. MyoD seemed a good candidate for compensation since it is, albeit weakly, expressed in *Myf-5* mutant embryos at the 35-somite stage when no other myogenic factors have yet been activated. We therefore closely followed the appearance of MyoD mRNA in 40-somite embryos (E10.75) and compared it to the expression of other myogenic differentiation markers. The rostrocaudal direction of somite development allows the simultaneous observation of mature and immature somites on appropriate sections of the same embryo and a direct assessment of the sequence of myogenic factor expression.

As shown in Fig. 4A,B, strong MyoD hybridization signals were detected in somites of *Myf-5* mutant embryos at the 40-somite stage. The intensity and distribution of these signals were

comparable to those in wild-type littermates (Fig. 4E,F). Hybridization of adjacent sections to a myogenin probe revealed that myogenin mRNA was also expressed in the mature cranial somites where MyoD was already present.




Fig. 2. No myogenic factor is expressed in *Myf-5* mutant embryos (35 somites) until MyoD expression is initiated. In situ hybridization of cryostat sections of *Myf-5* mutant embryos to MyoD (A,B), myogenin, (C,D), Myf-6 (E,F) and Pax-3 (G,H) probes. Hybridization of adjacent cranial sections demonstrate that MyoD is the first myogenic factor which is expressed in *Myf-5* mutants. The first MyoD-positive somites are indicated by arrowheads. The strong Pax-3 hybridization signals ascertain the plane of the section through the dermomyotome. Left panel: dark-field illumination, right panel: bright field-illumination. Magnification is 250 \times .

However, in the less mature, caudal somites where MyoD expression was just beginning, no myogenin mRNA was found (Fig. 4C,D). Thus, the sequential appearance of myogenin and MyoD mRNA in wild-type embryos appeared to be reversed in the absence of Myf-5. This observation suggests that myogenin expression in mutant embryos is triggered by MyoD, whereas in wild-type embryos Myf-5 seems to activate myogenin transcription.

It has been shown previously that myogenin protein appears only 2 days after the accumulation of myogenin mRNA presumably due to translational control or decreased half life of the protein (Cusella-DeAngelis et al., 1992). Therefore, it was of interest to compare directly the appearance of MyoD RNA with that of myogenin protein and additional muscle-specific differentiation markers. For this, adjacent sections from cranial and caudal regions of 37-somite embryos were hybridized to a MyoD cRNA probe (Fig. 5A-C) and reacted with antibodies against myogenin (Fig. 5D-F) or MyHC (=Myosin Heavy Chain) (Fig. 5G-I), respectively. The first nuclei positive for myogenin protein appeared in cranial somites of *Myf-5* mutant embryos when MyoD mRNA was already weakly expressed (Fig. 5A,D). In contrast, caudal somites of the same embryo which were still negative for MyoD also lacked myogenin protein (Fig. 5B,E). Similarly, other terminal differentiation markers, such as MyHC, were detected in somites after MyoD and myogenin activation (Fig. 5G-H). As a positive control, sections of wild-type embryos were reacted with anti-myogenin antibodies (Fig. 5F) and anti-MyHC antibodies (Fig. 5I). Both antibodies strongly stained myotomal cells of 37-somite wild-type embryos. These results suggest that myogenin protein synthesis follows immediately after the expression of MyoD and the accumulation of myogenin RNA in mutant *Myf-5* embryos. Subsequently, other terminal differentiation markers follow.

Between E10.5 and E11.5 of embryo development the prospec-

tive muscle-forming areas increase from a small part in the somite to occupy a major portion of the mesodermal space (Kaufman, 1992). This rapid proliferation of myogenic cells appeared to be unaltered in *Myf-5* mutant embryos. Fig. 6 compares the distribution of MyoD and myogenin RNA




Fig. 3. HE- and immunohistochemical staining of E10.5 wild-type (A,C,E,G) and *Myf-5* mutant embryos (B,D,F,H). Transverse sections of staged and genotyped E10.5 embryos (40 somites) were either stained with haematoxylin/eosin (A,B) or reacted with monoclonal antibodies against titin (C,D), sarcomeric MyHC (E,F) and nebulin (G,H). Bound antibodies were visualized with secondary antibodies and the peroxidase reaction. In *Myf-5* mutant embryos, no immunoreactive cells were detectable whereas the myotome is clearly stained in wild-type embryos. Myotomes in wild-type embryos and dermomyotomal areas in *Myf-5* mutant embryos are marked by arrows. Magnification is 200 \times .

producing cells in limb sections of E11.5 embryos. No difference in intensity or frequency of myogenic factor producing cells could be detected between mutant (Fig. 6A-D) and wild-type (Fig. 6E-H) embryos. Similar results were also obtained using antibodies against MyHC, desmin and sarcomeric actin (data not shown). The development of deep axial muscles and superficial body wall muscles were also indistinguishable between wild-type and mutant embryos at E11.5.

Limb muscle precursor cells migrate normally to limb buds in the absence of myogenic factors

In recent studies, it has been demonstrated that the paired-box-containing gene *Pax-3* is expressed in a continuous domain from the dermomyotome to the limb buds which is consistent with the idea that it marks cells migrating from the lateral edge of the dermomyotome (Bober et al., 1994; Goulding et al., 1994; Williams and Ordahl, 1994). These cells most likely represent the prospective myoblasts of the limb (Ordahl and LeDouarin, 1992). We used *Pax-3* as a molecular marker to investigate the fate of prospective limb muscle cells in E10.25 *Myf-5* mutant mice (32 somites).

Interestingly, the migration of *Pax-3*-positive cells from the dermomyotome to the limb buds appeared to be unaltered in *Myf-5* mutant (Fig. 7A) as compared to wild-type embryos (Fig. 7D). *Pax-3*-positive cells were found to leave the lateral edge of the dermomyotome and to populate the limb buds at a stage when no myogenic factor was present in somites or elsewhere in *Myf-5* mutants. The absence of myogenin and *Myf-6* was confirmed by in situ hybridization to adjacent sections of the same embryo (Fig. 7B,C). In contrast, wild-type embryos of this stage showed expression of both, myogenin and *Myf-6* (Fig. 7E-F) in somites but not in limb buds. As already demonstrated in Figs 1 and 2, the dermomyotomal expression domain of *Pax-3* was not reduced in mutant embryos at day 10.25. Furthermore, these cells were arranged in the

prospective muscle-forming areas of the limb buds which is compatible with their fate as future limb muscle cells.

Taken together these observations suggest that myogenic factors and the formation of a myotome, as defined by expression of myotomal markers, are not necessary to initiate or maintain the migration of prospective muscle cells to the limb buds.




Fig. 4. MyoD precedes the expression of myogenin in the caudal somites of *Myf-5* mutant embryos at the 40-somite stage. Adjacent sections of *Myf-5* mutant (A-D) or wild-type (E-H) embryos were hybridized to MyoD (A,B,E,F) or myogenin (C,D,G,H) probes. In *Myf-5* mutants myogenin transcripts were present only in MyoD-expressing somites, whereas in wild-type embryos myogenin mRNA is already present in the most caudal somites prior to MyoD mRNA. The most caudal MyoD-positive somite of the mutant embryo begins to accumulate myogenin transcripts (marked by the arrowhead). Left panel: dark-field illumination, right panel: bright-field illumination. Magnification is 250 \times .




Fig. 5. Comparison of MyoD mRNA (A-C) myogenin protein (D-F) and MyHC protein (G-I) expression on adjacent sections through cranial and caudal somites of the *Myf-5* mutant (A,B,D,E,G,H) and wild-type (C,F,I) embryos at the 37-somite stage. Myogenin protein (D) appears in cranial somites of *Myf-5* mutants only when the MyoD signals (A) are detectable. MyHC is still not expressed at this stage in mutant embryos (G). In caudal somites neither MyoD mRNA (B) nor myogenin (E) or MyHC (H) protein was detected. In wild-type embryos MyHC-positive (I) and myogenin-positive cells (F) are clearly detectable by antibody staining. A MyoD mRNA and myogenin protein-positive somite is marked by arrows. First row: dark-field illumination, second and third row: bright-field illumination. Magnification is 500 \times .

DISCUSSION

The experiments described here were undertaken to analyze early myotome development and the expression pattern of myogenic bHLH genes in *Myf-5* mutant embryos. In addition, we supply evidence that the migratory cells for the prospective limb muscles which arise in the dermomyotome develop independently of the expression of myogenic regulatory factors and of early myotome development.

Our observations demonstrate that myogenic differentiation can be initiated in two waves during somite development. The first wave is dependent on *Myf-5* expression: lack of *Myf-5* results in a loss of expression of the myogenic factors myogenin and *Myf-6* and consequently in lack of myogenic differentiation. The second wave coincides with the activation of *MyoD* which occurs at the appropriate developmental stage independently of *Myf-5* or any other myogenic bHLH factor.

In double-mutant mice that are defective for both *Myf-5* and *MyoD*, no myocytes and presumably no myoblasts arise (Rudnicki et al., 1993). These observations nicely support a model for myogenesis, which appears strictly dependent on

these two factors: if both waves of muscle development are prevented myogenic differentiation is completely abolished.

As skeletal muscle development appears to proceed normally when *MyoD* becomes activated even in the absence of *Myf-5*, *MyoD* gene activation marks an autonomous and alternative entry point for myogenic precursors into the muscle differentiation pathway.

The existence of two separate and apparently unlinked entries into skeletal muscle development, one controlled by *Myf-5* and another controlled by *MyoD*, is an unexpected result. The lack of qualitative differences in fetal and perinatal skeletal muscle between wild-type and *Myf-5* and *MyoD* mutant animals argues that *Myf-5* and *MyoD* probably do not direct the formation of functionally different muscle lineages during prenatal development. It is rather likely that both genes receive and integrate different signals that ensure the establishment and propagation of one type of skeletal muscle progenitors. In this context, it is interesting to note that *MyoD* expression starts just before the massive growth of the muscle cell compartment occurs between E10.5 and E11.5, which might explain why muscle differentiation proceeds virtually normal at E11.5 in *Myf-5* mutant mice.

Undoubtedly, *Myf-5* and *MyoD* genes are activated in

response to different developmental signals; however, their biochemical functions in cells appears largely overlapping or redundant. This hypothesis is supported in *MyoD* knock-out mice, which lack a muscle phenotype most probably due to an enhanced expression of *Myf-5* suggesting that *Myf-5* can substitute for *MyoD* and may maintain late somitic muscle development. At present, it is not clear whether the lack of a muscle phenotype in *MyoD* mutant mice is due to numerical increase of early *Myf-5*-dependent somitic myoblasts or whether *Myf-5* is expressed de novo in mesodermal cells that were not yet committed to the muscle fate. This is not a trivial problem since, in the latter case, the *Myf-5* promoter would have to be activated by the same signals that switch on the *MyoD* promoter during later somitic development. The other possibility would require an expansion of *Myf-5*-expressing early somitic cells in the absence of *MyoD*-positive myoblasts. In wild-type development *MyoD*-expressing cells largely replace the population of *Myf-5*-expressing myoblasts.

Interestingly, when homozygous mutant *Myf-5* ES-cells were differentiated in vitro, skeletal muscle cells emerged at the same time as in wild-type ES-cells expressing the same set of muscle markers. Simultaneously, *MyoD* expression occurred earlier in *Myf-5* mutant cells (Braun and Arnold, 1994). The premature expression of *MyoD* in vitro as compared to its unaltered expression in vivo in the *Myf-5* mutant embryos may indicate that the *MyoD* gene is under negative regulatory influence in vivo repressing the occurrence of *MyoD* in early somitic myoblasts. This effect seems to be bypassed in vitro.

Given the view that *Myf-5* and *MyoD* triggered waves of myogenic differentiation yield qualitatively similar muscle cells, it remains enigmatic whether these different entry points into the myogenic lineage serve distinct functions. If either of the pathways is dispensable for later myogenesis as long as the other is operative, why are there different pathways at all? An extreme view would be that the somitic myotome between E8.5 and E10.5 is an evolutionary remnant in today's animals unnecessary for muscle development but required for cell interactions within the somite. Such interactions might be essential to set up correct bound-

aries and/or growth stimulation or differentiation of adjacent cell types like sclerotomal cells giving rise to the ribs. However, if the second entry into the myogenic lineage has been eliminated, the ancient differentiation pathway can take over with the result that functional musculature develops.

The limited set of data available for *Myf-5*-deficient muscle, however, can not rule out the possibility that *Myf-5* or cells derived from the early myotome play yet unidentified roles for muscle development. Postnatally, at later stages of muscle development, this may include the generation of different muscle fiber types and myogenic cell diversity as suggested




Fig. 6. The level of myogenin and *MyoD* expression is indistinguishable in E11.5 *Myf-5* mutant and wild-type embryos. Limb sections of *Myf-5* mutant (A-D) and wild-type (E-H) embryos were hybridized to myogenin (A,B,E,F) or *MyoD* (C,D,G,H) probes. Differences are no longer detectable suggesting that muscle cells development continuous normal from E11.5. Left panel: dark-field illumination, right panel: bright-field illumination. Magnification is 320 \times .

recently (Smith et al., 1993; Hughes et al., 1993), although *Myf-5* and *MyoD*-expressing myoblasts seem to be equivalent at early stages. The use of homozygous *Myf-5* mutant ES-cells to generate chimeras and/or the employment of conditional *Myf-5* mutations will allow a more detailed molecular and physiological analysis in the future.

In a recent study, Bober et al. (1994) have shown that the paired-box-containing gene *Pax-3* is expressed in a population

of migrating limb muscle precursor cells. In addition *Pax-3* is expressed in dermomyotomal and myotomal regions which partially overlap the normal expression domains of *Myf-5*. In this study, we have demonstrated that *Pax-3* displays an apparently normal expression pattern both in somites and in migratory limb muscle precursor cells of *Myf-5* mutant embryos.

The apparently normal expression of *Pax-3* in mesodermal




Fig. 7. Comparison of *Pax-3*, myogenin and *Myf-6* expression in somites and forelimbs of mutant *Myf-5* (A-C) and wild-type (D-F) embryos at the 32-somite stage. Broken lines indicate the contours of the forelimbs. Adjacent cryostat sections were hybridized to *Pax-3* (A,D), myogenin (B,E) and *Myf-6* (C,F). *Pax-3*-positive cells are present in the forelimbs of *Myf-5* mutants despite the absence of myogenin (B) and *Myf-6* (C). Wild-type embryos show expression of myogenin (E) and *Myf-6* (F) in addition to *Pax-3* expression (D). Dark-field illumination only is shown. Magnification is 125 \times .

structures of the dermomyotome and the prospective limb muscle cells might indicate that the mesodermal cells that receive their myogenic commitment by the expression of Myf-5 are still present in mutant embryos. They probably maintain their mesodermal fate unless MyoD expression commences rescuing their myogenic determination. Later during development, however, undetermined mesodermal cells are most likely sequestered because double homozygous *Myf-5* and *MyoD* mutant mice show no undifferentiated mesodermal tissue in positions where muscle is normally located (Rudnicki et al., 1993; Braun et al., unpublished observations). In addition, the normal migration of Pax-3-positive limb muscle precursor cells from dermomyotome of *Myf-5* mutant embryos at a time when no myogenic factors are present demonstrates that migration of limb muscle precursors is independent from commitment involving myogenic bHLH proteins. These findings corroborate previous studies that were unable to locate myogenic bHLH gene expression in the most lateral dermomyotomal cells and in the population of migrating cells (Bober et al., 1991; Tajbakhsh and Buckingham, 1994). In addition, it seems now very unlikely that committed myogenic cells orchestrate the emigration of prospective limb muscle cells or have a pioneering influence on lateral dermomyotomal cells which have not received their final commitment.

In summary, we have demonstrated that Myf-5 is responsible for the first developmental events that are specific for the muscle cell lineage. A later wave of myogenic differentiation however, critically depends on expression of MyoD or alternatively on a sustained and enhanced expression of Myf-5.

We would like to thank K. Weber, W. E. Wright and D. Fishman for antibody reagents and P. Gruss for the Pax-3 cDNA probe. The excellent technical assistance of S. Heymann is gratefully acknowledged. This work was supported by the SFB 271: 'Molekulare Mechanismen morphoregulatorischer Prozesse' and by a grant from Deutsche Forschungsgemeinschaft to T. B.

REFERENCES

- Arnold, H.-H. and Braun, T. (1993). Myogenic control genes in vertebrates. In *Advances in Developmental Biology* (ed. P. M. Wassarman). pp. 111-158. Greenwich: JAI Press.
- Bober, E., Lyons, G. E., Braun, T., Cossu, G., Buckingham, M. and Arnold, H. H. (1991). The muscle regulatory gene, Myf-6, has a biphasic pattern of expression during early mouse development. *J. Cell. Biol.* **113**, 1255-65.
- Bober, E., Franz, T., Arnold, H.-H., Gruss, P. and Tremblay, P. (1994). Pax-3 is required for the development of limb muscles: a possible role for the migration of dermomyotomal muscle progenitor cells. *Development* **120**, 603-612.
- Braun, T., Bober, E., Buschhausen, D. G., Kohtz, S., Grzeschik, K. H. and Arnold, H. H. (1989). Differential expression of myogenic determination genes in muscle cells: possible autoactivation by the Myf gene products. *EMBO J.* **8**, 3617-25.
- Braun, T., Rudnicki, M. A., Arnold, H.-H. and Jaenisch, R. (1992). Targeted inactivation of the muscle regulatory gene Myf-5 results in abnormal rib development and perinatal death. *Cell* **71**, 369-382.
- Braun, T. and Arnold, H.-H. (1994). ES-cells carrying two inactivated Myf-5 alleles form skeletal muscle cells: Activation of an alternative Myf-5-independent differentiation pathway. *Dev. Biol.* **164**, 24-36.
- Buckingham, M. (1992). Making muscles in mammals. *Trends Genet.* **8**, 144-148.
- Christ, B., Jacob, H. and Jacob, B. (1978). On the formation of the myotomes in avian embryos. An experimental and scanning electron microscope study. *Experientia* **34**, 514-516.
- Cossu, G. and Molinaro, M. (1987). Cell heterogeneity in the myogenic lineage. *Curr. Top. Dev. Biol.* **23**, 185-208.
- Cusella-DeAngelis, M. G., Lyons, G., Sonnino, C., DeAngelis, L., Vivarelli, E., Farmer, K., Wright, W. E., Molinaro, M., Bouche, M., Buckingham, M. and Cossu, G. (1992). MyoD, myogenin independent differentiation of primordial myoblasts in mouse somites. *J. Cell. Biol.* **116**, 1243-1255.
- Goulding, M. D., Chalepakis, G., Deutsch, U., Erselius, J. R. and Gruss, P. (1991). Pax-3, a novel murine DNA-binding protein expressed during early neurogenesis. *EMBO J.* **10**, 1135-1147.
- Goulding, M., Lumsden, A. and Paquette, A. J. (1994). Regulation of PAX-3 expression in the dermomyotome and its role in muscle development. *Development* **120**, 957-971.
- Hasty, P., Bradley, A., Morris, J. H., Edmundson, D. G., Venuti, J., Olson, E. N. and Klein, W. H. (1993). Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. *Nature* **364**, 501-506.
- Hinterberger, T. J., Sassoon, D. A., Rhodes, S. J. and Konieczny, S. F. (1991). Expression of the muscle regulatory factor MRF4 during somite and skeletal myofiber development. *Dev. Biol.* **147**, 144-56.
- Hughes, S. M., Taylor, J. M., Tapscott, S. J., Gurley, C. M., Carter, W. J. and Peterson, C. A. (1993). Selective accumulation of MyoD and myogenin mRNAs in fast and slow adult skeletal muscle is controlled by innervation and hormones. *Development* **118**, 1137-1147.
- Kaufman, M. H. (1992). *The Atlas of Mouse Development*. London: Academic Press.
- Keynes, R. and Stern, C. (1988). Mechanisms of vertebrate segmentation. *Development* **103**, 413-429.
- Nabeshima, Y., Hanaoka, K., Hayasaka, M., Esumi, E., Li, S., Nonaka, I. and Nabeshima, Y. (1993). Myogenin gene disruption results in perinatal lethality because of severe muscle defect. *Nature* **364**, 532-535.
- Olson, E. N. and Klein, W. H. (1994). bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out. *Genes Dev.* **8**, 1-8.
- Ordahl, C. P. and LeDouarin, N. (1992). Two myogenic cell lineages within the developing somite. *Development* **114**, 339-353.
- Ott, M. O., Bober, E., Lyons, G., Arnold, H. and Buckingham, M. (1991). Early expression of the myogenic regulatory gene, Myf-5, in precursor cells of skeletal muscle in the mouse embryo. *Development* **111**, 1097-107.
- Rudnicki, M. A., Braun, T., Hinuma, S. and Jaenisch, R. (1992). Inactivation of MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal muscle development. *Cell* **71**, 383-390.
- Rudnicki, M. A., Schnegelsberg, P. N. J., Stead, R. H., Braun, T., Arnold, H. H. and Jaenisch, R. (1993). MyoD or Myf-5 is required for the formation of skeletal muscle. *Cell* **75**, 1351-1359.
- Sassoon, D., Lyons, G., Wright, W. E., Lin, V., Lassar, A., Weintraub, H. and Buckingham, M. (1989). Expression of two myogenic regulatory factors myogenin and MyoD1 during mouse embryogenesis. *Nature* **341**, 303-7.
- Smith, T. H., Block, N. E., Rhodes, S. J., Konieczny, S. F. and Miller, J. B. (1993). A unique pattern of expression of the four muscle regulatory factor proteins distinguishes somitic from embryonic, fetal and newborn mouse myogenic cells. *Development* **117**, 1125-1133.
- Tajbakhsh, S. and Buckingham, M. (1994). Mouse limb muscle is determined in the absence of the earliest myogenic factor myf-5. *Proc. Natl. Acad. Sci. USA* **91**, 747-751.
- Weintraub, H., Davis, R., Tapscott, S., Thayer, M., Krause, M., Benezra, R., Blackwell, T. K., Turner, D., Rupp, R., Hollenberg, S., Zhuang, Y. and Lassar, A. (1991). The MyoD Gene family: nodal point during specification of the muscle cell lineage. *Science* **251**, 761-766.
- Williams, B. A. and Ordahl, C. P. (1994). Pax-3 expression in segmented mesoderm marks early stages in myogenic cell specification. *Development* **120**, 785-796

(Accepted 8 August 1994)